September 2021 FAQs
- What evidence is available for use of the newest mineralocorticoid receptor antagonist, finerenone, in diabetic kidney disease?
- Are there any data to support administration of a second course of intravenous immunoglobulin in patients with Guillain-Barré syndrome unresponsive to a first course?
- 2021 Update: What are considerations for determining whether a drug may be administered via a midline catheter?